Briakinumab for the treatment of moderate to severe chronic plaque psoriasis (suspended)
Following on from information provided to NICE by the company in April 2018 the appraisal of Psoriasis – briakinumab [ID65] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 65
Referral date 01 November 2008
Topic area
  • Skin

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Assessment Group / Evidence Review Group: TBC
Communications manager: TBC
Executive Lead: TBC
Project manager: TBC
Technical Lead: TBC

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
16 November 2022 Following on from information provided to NICE by the company in April 2018 the appraisal of Psoriasis – briakinumab [ID65] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
16 November 2022 Discontinued. Following on from information provided to NICE by the company in April 2018 the appraisal of Psoriasis – briakinumab [ID65] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
23 February 2011 The Institute has been informed by the manufacturer that it has withdrawn its application for a centralised marketing authorisation for briakinumab, as the additional new data and analyses thought to be required for a favourable opinion could not be generated within the timeframe allowed in the centralised procedure. For further information please click on the following link: http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---January/17/Marketing-authorisation-application-for-briakinumab-Ozespa-withdrawn-/

NICE has therefore decided to suspend this appraisal on its current work programme for the time being.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

For further information on our processes and methods, please see our CHTE processes and methods manual